Ocugen
Ocugen's revenue rose 8.8% to $4 million in fiscal 2025. Its operating margin was −1,425.7%, down from −1,350.4% a year earlier. Free cash flow was −$57 million.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Ocugen does
Ocugen is a clinical-stage biotechnology company working on gene therapies for eye diseases that can cause blindness. It has no approved products, so it has no product sales. It describes its main approach as a modifier gene therapy platform, built on nuclear hormone receptors, that it hopes can treat diseases without depending on which gene mutation a patient has.
Its lead candidate, OCU400, is for retinitis pigmentosa, an inherited disease of the retina. It has finished enrolling its Phase 3 trial and says it plans to begin a rolling submission of a biologics license application (BLA) to the FDA in the third quarter of 2026. A second candidate, OCU410ST, is in a Phase 2/3 pivotal confirmatory trial for Stargardt disease, and the company plans a BLA for it in the first half of 2027. A third, OCU410, is in a Phase 1/2 trial for geographic atrophy, an advanced form of dry age-related macular degeneration. It also has an early-stage protein drug, OCU200, for diabetic eye disease and wet age-related macular degeneration.
Without product revenue, it pays for its work by raising money. As of February 24, 2026, it had 116 employees, 79 of them in the United States, 34 in India and three in Canada.
Its biggest risks, as it describes them
- It has lost money since it began and expects to need substantial new funding, which may not be available.
- It has never sold a medicine, and its candidates may fail in trials or be denied regulatory approval.
- Its gene therapies use a new technology with an uncertain regulatory path.
- Clinical trials may be delayed, and early results may not predict later ones.
- Making biologic medicines is complex and carries its own risks.
Income statement
Ocugen lost money in fiscal 2025: a net loss of $68 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 95 | 91 | 40 | 59 | 19 |
| Debt incl. finance leases | 2 | 2 | 3 | 29 | 29 |
| Net debt (negative means net cash) | −93 | −89 | −37 | −30 | 10 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.0x | 0.0x | 0.1x | 1.0x | — |
| Interest coverage | −734.5x | — | — | −79.6x | −12.1x |
| Current ratio | 14.7x | 3.5x | 2.5x | 2.9x | 1.1x |
| Quick ratio | 14.7x | 3.5x | 2.5x | 2.9x | 1.1x |
Cash flow
Projections
Project Ocugen's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $25,830 of Ocugen shares on the open market, and 1 insider sold $589,110, all of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 9, 2026 | Shankar MusunuriChief Executive Officer, Director | Sold plan | 525,991 | $1.12 | $589,110 | Form 4 |
| Jun 15, 2026 | Treerita Essalima Johnson-GreeneChief Financial Officer | Bought | 21,000 | $1.23 | $25,830 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 3 of 8 | — | — |
| Rule of 40 | −1,059.0% | −1,155.6% | −1,286.2% |
| Altman Z'' | −16.87 | −14.14 | −40.32 |
| Accruals ratio | −1.2% | −16.2% | −17.3% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Fail | Fail |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | Fail | — | — |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Pass | Pass | Fail |
| F-score | 3 of 8 | — | — |
Compare
Put Ocugen side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Ocugen | FY25 | 8.8% | −1,425.7% | −1,295.0% | — | — | — | |
| Prime Medicine | FY25 | 55.3% | −4,498.1% | −3,607.4% | — | — | — | Compare |
| CG Oncology | FY25 | 254.7% | −4,722.1% | −3,279.2% | — | — | 2 | Compare |
| Cerenome | FY25 | −10.5% | −293.5% | −399.8% | — | — | — | Compare |
| CRISPR Therapeutics | FY25 | −90.6% | −18,933.7% | −9,855.5% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 6 | 4 | 4 |
| Revenue growth | — | — | — | — | — | −100.0% | — | 142.6% | −32.8% | 8.8% |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Research and development | 22 | 16 | 10 | 8 | 6 | 35 | 56 | 40 | 32 | 40 |
| Operating income | −30 | −25 | −16 | −14 | −21 | −58 | −89 | −66 | −55 | −63 |
| Net income | −16 | −26 | −18 | −20 | −22 | −58 | −87 | −63 | −54 | −68 |
| Diluted EPS (US$) | −2.18 | −0.99 | −0.79 | −1.46 | −0.31 | −0.30 | −0.40 | −0.26 | — | — |
| Diluted shares (millions) | 14 | 23 | 37 | 14 | 112 | 195 | 215 | 244 | — | — |
| Cash flow | ||||||||||
| Cash from operations | −26 | −23 | −12 | −17 | −15 | −48 | −60 | −62 | −42 | −57 |
| Capital expenditure | 0 | 0 | 0 | 0 | 0 | 1 | 4 | 10 | 3 | 0 |
| Free cash flow | −26 | −23 | −12 | −17 | −15 | −49 | −65 | −73 | −46 | −57 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 2 | 2 | 2 | 1 | 1 | 7 | 10 | 9 | 7 | 8 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 32 | 8 | — | 7 | 24 | 95 | 91 | 40 | 59 | 19 |
| Debt incl. finance leases | — | — | 8 | 1 | 2 | 2 | 2 | 3 | 29 | 29 |
| Total assets | 36 | 11 | 2 | 17 | 27 | 106 | 109 | 64 | 82 | 44 |
| Total liabilities | 22 | 22 | 15 | 6 | 6 | 10 | 35 | 24 | 53 | 56 |
| Shareholders' equity | 14 | 4 | −13 | 11 | 22 | 91 | 74 | 41 | 30 | −12 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | −49,500.0% | — | −3,580.0% | −1,085.7% | −1,350.4% | −1,425.7% |
| Net margin | — | — | — | — | −50,748.8% | — | −3,488.9% | −1,045.0% | −1,333.0% | −1,537.4% |
| Free cash flow margin | — | — | — | — | −34,920.9% | — | −2,593.9% | −1,201.6% | −1,122.7% | −1,295.0% |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | — | — | −1,059.0% | −1,155.6% | −1,286.2% |
| Return on capital | — | — | — | — | −750.5% | — | — | — | — | — |
| Return on equity | −77.6% | −293.5% | — | — | −134.0% | −103.5% | −105.1% | −110.1% | −154.0% | −776.9% |
| Return on assets | −44.5% | −112.1% | −270.1% | −210.2% | −98.8% | −87.7% | −81.0% | −72.8% | −73.5% | −107.7% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |